Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
出版年份 2019 全文链接
标题
Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
作者
关键词
-
出版物
CANCER
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-06-28
DOI
10.1002/cncr.32339
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer
- (2018) Chenlu Zhang et al. BMC CANCER
- Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma
- (2018) Valerie Chew et al. GUT
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
- (2018) Karin M. Knudson et al. OncoImmunology
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
- (2018) Rikke B. Holmgaard et al. Journal for ImmunoTherapy of Cancer
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer
- (2018) SHINKICHI TAKAMORI et al. ANTICANCER RESEARCH
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
- (2017) Rachel M. Gibbons Johnson et al. Frontiers in Immunology
- PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis
- (2016) Omar Abdel-Rahman Immunotherapy
- Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
- (2016) Jessica L. Petrick et al. JOURNAL OF CLINICAL ONCOLOGY
- Pseudoprogression and Immune-Related Response in Solid Tumors
- (2015) Victoria L. Chiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis
- (2015) Laëtitia Basset et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Roles for Chemokines in Liver Disease
- (2014) Fabio Marra et al. GASTROENTEROLOGY
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
- (2013) M. Sznol et al. CLINICAL CANCER RESEARCH
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Interferon γ-induced intratumoral expression of CXCL9 alters the local distribution of T cells following immunotherapy withListeria monocytogenes
- (2013) Patrick Guirnalda et al. OncoImmunology
- Radiofrequency Thermal Ablation for Hepatocellular Carcinoma Stimulates Autologous NK-Cell Response
- (2010) Alessandro Zerbini et al. GASTROENTEROLOGY
- T-cell exhaustion: characteristics, causes and conversion
- (2010) John S. Yi et al. IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More